Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status:
Terminated
Trial end date:
2016-10-20
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well haploidentical donor hematopoietic stem cell transplant
works in treating patients with hematologic malignancies. Giving chemotherapy and total-body
irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may
also stop the patient's immune system from rejecting the donor's stem cells. Giving an
infusion of the donor's T cells (donor lymphocyte infusion) may replace the patient's immune
cells and help destroy any remaining cancer cells. When the stem cells from a related donor,
that closely matches the patient's blood, are infused into the patient they may help the
patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University